{"id":"W4380078993","doi":"10.1002/hon.3163_80","title":"SAKK 35/14 RANDOMIZED TRIAL OF RITUXIMAB WITH OR WITHOUT IBRUTINIB FOR UNTREATED PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA IN NEED OF THERAPY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Calvary Mater Newcastle; National Institutes of Health; Masarykova Univerzita; Barts Health NHS Trust; BeiGene; Institut Bergonié; Tianjin Medical University; Peking University; Università degli Studi dell'Insubria; Jewish General Hospital; Harbin Medical University","keywords":"Medicine; Rituximab; Follicular lymphoma; Ibrutinib; Internal medicine; Hazard ratio; Ofatumumab; Randomized controlled trial; Clinical endpoint; Lymphoma; Placebo; Randomization; International Prognostic Index; Surgery; Oncology; Gastroenterology; Confidence interval; Leukemia; Chronic lymphocytic leukemia; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008763623,0.0002932223,0.003196989,0.000298582,0.00003731828,0.000004470624,0.0001947987,0.000390761,0.0001028301],"category_scores_gemma":[0.001571948,0.0001440535,0.0002170618,0.001008708,0.0007598033,0.00004826011,0.00006516047,0.0001439243,0.000008515281],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001325468,"about_ca_system_score_gemma":0.003860492,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001135823,"about_ca_topic_score_gemma":0.00006738181,"domain_scores_codex":[0.9969929,0.0003703863,0.0009896007,0.0004844012,0.0005582076,0.0006044724],"domain_scores_gemma":[0.9952866,0.003302553,0.0004508183,0.0004103778,0.0003957292,0.0001538598],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9861788,0.003479441,0.003787813,0.0002565698,0.0003538509,0.0003010675,0.0002275949,0.00002678841,0.0002236516,0.0003112816,0.0001029731,0.004750185],"study_design_scores_gemma":[0.9698297,0.02197678,0.0006050596,0.000251044,0.0001387982,0.000103558,0.0001682836,0.002446131,0.003665897,0.0001641868,0.0004796255,0.0001709056],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908166,0.0001072877,0.0001689338,0.0003192106,0.00006674043,0.007893152,0.00001553571,0.00008658563,0.0005259449],"genre_scores_gemma":[0.9952217,0.000176484,0.002896769,0.0001201753,0.00002554327,0.00124174,0.0001033576,0.00004057852,0.0001736416],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01849734,"threshold_uncertainty_score":0.6848347,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0345031175598008,"score_gpt":0.3562166182791113,"score_spread":0.3217135007193105,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}